Kamada Raises 2026 Revenue and EBITDA Forecasts
The Israeli biopharmaceutical company reported third-quarter revenue growth of 11% and lifted its full-year outlook.
Updated on Nov. 10, 2026 in Corporate Finance

Kamada Ltd. reported third-quarter revenue of $52 million, up from $47 million a year earlier, and net income that rose 51% to $8 million, or $0.14 per diluted share. The company raised its 2026 revenue forecast to $205 million-$208 million and its adjusted EBITDA forecast to $52 million-$54 million.
Why it matters
The higher guidance reflects improved margins on proprietary products, with gross margin climbing to 45% from 42%. The results suggest growing profitability as Kamada expands its plasma collection operations and biosimilar portfolio.
Gross profit rose to $23.3 million from $19.8 million, and distribution-segment revenue increased 35% to $24.1 million in the first nine months of 2026. Whether margin gains will hold as plasma supply ramps up has not been addressed in the report.
The players
Kamada Ltd.
Kamada is an Israeli biopharmaceutical company that develops and markets plasma-derived therapies and biosimilar products.
The details
Kamada attributed the margin improvement to higher margins on proprietary products, reflecting product and market mix. The company is ramping up plasma collection at its Texas facilities under a three-year supply agreement announced in July, which is expected to generate about $50 million in revenue, with initial commercial sales expected in the fourth quarter of 2026.
Timeline
July 2026: Three-year Texas plasma supply agreement announced.
Sept. 30, 2026: Third-quarter period ended.
Nov. 9, 2026: Third-quarter results released.
Fourth quarter of 2026: Initial commercial plasma sales expected.
January 2027: Detailed 2027 guidance planned.
Market Dynamics
Kamada's plasma expansion in Texas reflects a broader push by biopharmaceutical manufacturers to secure domestic plasma collection capacity. The company's biosimilar revenue targets for 2028 and 2030 place its growth strategy within an increasingly competitive market for lower-cost biologic alternatives.
Investors tracking Kamada's shares can use the raised 2026 forecasts and improved gross margin to assess the company's earnings trajectory. The timing of the planned January 2027 guidance release will be a near-term checkpoint for updated expectations.
The takeaway
Rising gross margins alongside revenue growth suggest Kamada's earnings gains are coming from its product mix rather than volume alone. Investors should watch the fourth-quarter start of plasma sales and the January 2027 guidance for confirmation.
What happens next
Kamada is expected to release detailed 2027 guidance in January 2027, and initial commercial sales under the Texas plasma supply agreement are expected in the fourth quarter of 2026.
Further reading
Explore more in Corporate Finance coverage.



